AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Vaccine Fund Will Allow Research With Prime-Boost Technology.(Brief Article)
2001 NOV 14 - (NewsRx.com & NewsRx.net) -- The director of the Malaria Vaccine Initiative has announced a two-year, $1.5 million partnership for research and testing of a malaria vaccine.
Dr. Regina Rabinovich said the Maryland-based initiative will team with the University of Oxford and a biotechnology company Oxxon Pharmaccines.
"Malaria has become an unseen epidemic but with the help of funding and partnerships, it is possible to see a vaccine in eight to 15 years," she said at the 129th meeting of the American Public Health Association.
Rabinovich said the alliance will allow development and testing in ...
- Oxxon Pharmaccines(TM) Melanoma Therapeutic Vaccine Enters Phase II Clinical...
- Press release article from: PR Newswire October 14, 2002 700+ words
OXFORD, England -- Oxxon Pharmaccines Ltd (Oxxon), a biotechnology company developing...survival is seven to nine months. Notes to Editors Oxxon Pharmaccines Oxxon Pharmaccines is a biotechnology company focused on the development...
- Oxxon Pharmaccines(TM) Raises 15 Million Pounds Sterling In International...
- Press release article from: PR Newswire April 14, 2003 700+ words
...England, April 14 /PRNewswire/ -- Oxxon Pharmaccines Ltd (Oxxon), a biotechnology company...development and commercial capabilities." Oxxon Pharmaccines is a product-based company with...international development." Notes Oxxon Pharmaccines Oxxon Pharmaccines is a ...
- Oxxon Pharmaccines raises #15 M in international funding round to drive...
- News wire article from: Asia Africa Intelligence Wire April 14, 2003 700+ words
...Chemical Business NewsBase - Press Release) Oxxon Pharmaccines Ltd (Oxxon) has raised #15 M in a private...College Fund (UK) also committed further funds. Oxxon Pharmaccines is a biotechnology company developing innovative...
- Press Release: Oxxon Pharmaccines melanoma therapeutic vaccine enters Phase II...
- News wire article from: Asia Africa Intelligence Wire October 14, 2002 700+ words
...Chemical Business NewsBase: Press Release) Oxxon Pharmaccines Ltd (Oxxon) announced that its melanoma pharmaccine...hepatitis B infection in Phase II clinical trials. Oxxon Pharmaccines Ltd is a biotechnology company focused on the...
- Oxxon Pharmaccines names Frank Malinoski as CMO.(Brief Article)
- Newspaper article from: Pharma Marketletter March 15, 2004 700+ words
Frank Malinoski has joined UK-based biotechnology company Oxxon Pharmaccines as chief medical officer. His previous appointment was that of vice president of global business development at Wyeth Vaccines.
- Oxxon Pharmaccines.(hepatitis B vaccine trials)(Brief Article)
- Newspaper article from: BioWorld International November 7, 2001 700+ words
* Oxxon Pharmaccines, of Oxford, UK, said its hepatitis B vaccine entered Phase I trials. This is the company's second product in the clinic...
- Oxxon Pharmaccines.(Movers & Shakers)(Brief Article)
- Magazine article from: Chemistry and Industry April 5, 2004 700+ words
Oxxon Pharmaccines (Oxxon) has announced the appointment of Frank Malinoski as executive vice president development & chief medical officer...
- Oxxon Pharmaccines Ltd.(Other News To Note)(Brief Article)
- Newspaper article from: BioWorld International January 21, 2004 700+ words
* Oxxon Pharmaccines Ltd., of Oxford, UK, was granted a U.S. patent on the generic use of its platform technology Heterologous PrimeBoost. The...
- Oxxon Pharmaccines Ltd. of Oxford, UK, strengthened its hold on the use of...
- Newspaper article from: BioWorld International April 17, 2002 700+ words
* Oxxon Pharmaccines Ltd., of Oxford, UK, strengthened its hold on the use of Modified Vaccinia virus Ankara (MKA) in therapeutic vaccines, agreeing...
- Oxxon Pharmaccines Ltd. (Other News To Note).
- Newspaper article from: BioWorld International October 16, 2002 700+ words
Oxxon Pharmaccines Ltd., of Oxford, UK, said its therapeutic melanoma vaccine has entered Phase II, following a successful Phase I trial showing...
Source: HighBeam Research, Vaccine Fund Will Allow Research With Prime-Boost Technology.(Brief...